Bluejay Diagnostics shares surge 10.19% intraday on SYMON-II trial progress and $4.5M financing.

Bluejay Diagnostics surged 10.19% intraday following a corporate update highlighting progress in its SYMON-II clinical trial, strategic manufacturing partnerships, and recent financings. The company announced it continues patient enrollment in the SYMON-II trial to validate the Symphony IL-6 test’s efficacy in predicting ICU mortality, with sample testing expected by late 2026 and a potential FDA submission in 2027. It also secured $3.85 million via a warrant-inducement financing in April and $4.5 million through a PIPE in October, strengthening its $3.08 million cash position. Additionally, Bluejay expanded its partnership with SanyoSeiko to enhance supply-chain independence and commercialization of the Symphony platform. These developments—advancing clinical milestones, securing capital, and strengthening manufacturing—collectively bolster investor confidence in the company’s near-patient diagnostics pipeline.